Breaking News Instant updates and real-time market news.

YGYI

Youngevity

$6.57

0.13 (2.02%)

, QFIN

360 Finance

$16.46

0.71 (4.51%)

18:55
05/20/19
05/20
18:55
05/20/19
18:55

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Youngevity (YGYI) up 2.1%... 360 Finance (QFIN) up 1.6%. ALSO HIGHER: Arrowhead Pharma (ARWR) up 6.0% after entering S&P SmallCap 600 index... TripAdvisor (TRIP) up 1.9% after being upgraded to Buy at Needham... Ascena Retail (ASNA) up 1.8% after announcing winddown of Dressbarn... Kroger (KR) up 1.2% after being upgraded to Outperform at Bernstein... Snap (SNAP) up 0.5% after naming new CFO. DOWN AFTER EARNINGS: Nordson (NDSN) down 2.5%. ALSO LOWER: Ocular Therapeutics (OCUL) down 8.9% after its OTX-TP failed to meet primary endpoint in Phase 3 trial... SolarWinds (SWI) down 5.8% after equity offering... Mercury Systems (MRCY) down 5.1% after equity offering... Veoneer (VNE) down 4.8% after equity offering... Guardant Health (GH) down 4.6% after equity offering... Carvana (CVNA) down 3.3% after equity offering... Insmed (INSM) down 2.7% after equity offering... Varian Medical (VAR) down 2.3% after acquiring Cancer Treatment Services and cutting FY19 guidance. Movers as of 18:45ET.

YGYI

Youngevity

$6.57

0.13 (2.02%)

QFIN

360 Finance

$16.46

0.71 (4.51%)

ARWR

Arrowhead

$18.94

-0.52 (-2.67%)

TRIP

TripAdvisor

$44.93

-0.07 (-0.16%)

ASNA

Ascena Retail

$1.13

-0.125 (-9.96%)

KR

Kroger

$24.04

-0.18 (-0.74%)

SNAP

Snap

$11.19

-0.3 (-2.61%)

NDSN

Nordson

$130.42

-4.8 (-3.55%)

OCUL

Ocular Therapeutix

$3.36

-0.1 (-2.89%)

SWI

SolarWinds

$19.16

0.04 (0.21%)

MRCY

Mercury Systems

$72.85

-0.11 (-0.15%)

VNE

Veoneer

$18.89

0.02 (0.11%)

GH

Guardant Health

$78.29

2.13 (2.80%)

CVNA

Carvana

$67.17

-0.935 (-1.37%)

INSM

Insmed

$28.08

-1.08 (-3.70%)

VAR

Varian Medical

$130.48

-0.26 (-0.20%)

  • 20

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 11

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Jun

  • 18

    Jun

  • 23

    Jun

  • 10

    Nov

  • 22

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

YGYI Youngevity
$6.57

0.13 (2.02%)

02/13/19
BNCH
02/13/19
NO CHANGE
Target $14
BNCH
Buy
Youngevity price target raised to $14 from $9 at Benchmark
Benchmark analyst Bill Sutherland noted that Youngevity announced the purchase of the assets of Khrysos Global, a Florida-based manufacturer of hemp-based CBD extraction equipment, which he said can be used to create a multi-faceted CBD vertical. After increasing his 2019 model to "conservatively" reflect Khrysos, which he believes will grow quickly, Sutherland raised his price target on Youngevity shares to $14 from $9 and keeps a Buy rating on the stock.
08/10/18
BNCH
08/10/18
INITIATION
Target $7
BNCH
Buy
Youngevity initiated with a Buy at Benchmark
Benchmark started Youngevity with a Buy rating and $7 price target.
08/10/18
08/10/18
INITIATION
Target $7

Buy
Benchmark starts Youngevity with Buy rating, $7 price target
As previously reported, Benchmark analyst Bill Sutherland started Youngevity with a Buy rating and $7 price target, stating that he believes the stock has yet to reflect a return to organic revenue growth and rising margins for the Direct Selling segment as well as a just-announced, 5-year green coffee bean supply contract that he believes should push the Coffee segment to "meaningful profitability" in 2019.
QFIN 360 Finance
$16.46

0.71 (4.51%)

05/14/19
CHRS
05/14/19
INITIATION
Target $29
CHRS
Buy
360 Finance initiated with a Buy at China Renaissance
China Renaissance analyst Jiang Zhang assumed coverage of China's fintech lenders, starting 360 Finance with a Buy rating and $29 price target, citing the company's exposure to the 360 Group ecosystem and its risk management expertise.
01/18/19
SBSH
01/18/19
INITIATION
Target $20.8
SBSH
Buy
360 Finance initiated with a Buy at Citi
Citi started 360 Finance with a Buy rating and $20.80 price target.
ARWR Arrowhead
$18.94

-0.52 (-2.67%)

11/12/18
PIPR
11/12/18
NO CHANGE
Target $25
PIPR
Overweight
Arrowhead's new data validate TRiM pipeline, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes new data presented by Arrowhead (ARWR) at the AASLD meeting on ARO-AAT and ARO-HBV validate the company's proprietary TRiM platform. He expects a potentially registrational Phase 2/3 trial for ARO-AAT to start in the first quarter of 2019 and noted that partner Janssen (JNJ) intends to begin Phase 2 studies of ARO-HBV in the first half of next year. Tenthoff keeps an Overweight rating and $25 price target on Arrowhead shares.
05/13/19
RILY
05/13/19
NO CHANGE
Target $26
RILY
Buy
Arrowhead price target raised to $26 from $19 at B. Riley FBR
B. Riley FBR analyst Mayank Mamtani raised his price target for Arrowhead Pharmaceuticals to $26 from $19 citing increased visibility into the company's three "high-value" cardio targets. The analyst sees "significant optionality" in Arrowhead's pipeline and he keeps a Buy rating on the shares. The analyst added ARO-APOC3 and ARO-ANG3 to his model, albeit with low probability of success given still the early stage of development. He keeps a Buy rating on the shares.
01/07/19
PIPR
01/07/19
NO CHANGE
PIPR
Piper Jaffray optimistic on Arrowhead as multiple studies commencing
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $25 price target on Arrowhead Pharmaceuticals after the company announced it dosed the first patient in Phase I ARO-ANG3 study and will commence Phase I dosing of ARO-APOC3 upon CTA approval. The analyst also sees at least two additional TRiM RNAi candidates entering the clinic in 2019, including ARO-ENaC and ARO-HIF2. Most important, Arrowhead will initiate a potentially registrational Phase II/III study for ARO-AAT in Q1 of 2019.
04/16/19
PIPR
04/16/19
NO CHANGE
Target $33
PIPR
Overweight
Arrowhead price target raised to $33 from $25 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals to $33 from $25 after the company received FDA clearance to start a Phase II/III trial of wholly-owned ARO-AAT in Alpha-1 antitrypsin deficiency. The analyst increased his value for ARO-AAT and reiterates an Overweight rating on Arrowhead shares.
TRIP TripAdvisor
$44.93

-0.07 (-0.16%)

05/20/19
NEED
05/20/19
UPGRADE
NEED
Buy
TripAdvisor upgraded to Buy from Hold at Needham
Needham analyst Brad Erickson assumed coverage on Trip Advisor with a Buy rating from a Hold rating.
05/09/19
LEHM
05/09/19
NO CHANGE
Target $70
LEHM
Overweight
TripAdvisor price target lowered to $70 from $78 at Barclays
Barclays analyst Deepak Mathivanan lowered his price target for TripAdvisor to $70 from $78 and keeps an Overweight rating on the shares following the company's Q1 results. TripAdvisor called out the potential impact from a softening macro environment in certain markets on sales performance in Q2 but reiterated its full year EBITDA growth guidance, Mathivanan tells investors in a post-earnings research note. The analyst says the macro comments weighed on an "otherwise stable print."
05/09/19
WEDB
05/09/19
NO CHANGE
Target $50
WEDB
Neutral
TripAdvisor price target lowered to $50 from $60 at Wedbush
Wedbush analyst James Hardiman lowered his price target for TripAdvisor to $50 from $60, noting that the shares were down about 11% on Wednesday, and given multiple consecutive disappointments that have now erased the entirety of the progress made over the past year. The analyst reiterates a Neutral rating on the shares.
05/09/19
DADA
05/09/19
NO CHANGE
Target $55
DADA
Neutral
TripAdvisor price target lowered to $55 from $62 at DA Davidson
DA Davidson analyst Tom White lowered his price target on TripAdvisor to $55 and kept his Neutral rating after its Q1 revenue miss that was driven by softer than expected demand in International markets. The analyst warns that based on the management's caution about auction-related revenue, these conditions have persisted in April. White adds that while TripAdvisor's Experiences and Dining businesses offer "interesting long-term opportunities", 2019 is setting up as "another relatively muted" year for the company's Hotel revenues.
ASNA Ascena Retail
$1.13

-0.125 (-9.96%)

06/05/18
RILY
06/05/18
NO CHANGE
Target $3.5
RILY
Neutral
Ascena Retail price target raised to $3.50 from $2.50 at B. Riley FBR
B. Riley FBR analyst Susan Anderson raised her price target for Ascena Retail Group to $3.50 saying same-store-sales improvement drove earnings to the high end of guidance in Q3. The analyst keeps a Neutral rating on the shares.
04/03/19
SBSH
04/03/19
UPGRADE
SBSH
Neutral
Ascena Retail upgraded to Neutral from Sell at Citi
Citi analyst Paul Lejuez upgraded Ascena Retail to Neutral from Sell.
04/03/19
SBSH
04/03/19
UPGRADE
Target $1
SBSH
Neutral
Ascena Retail upgraded to Neutral with unchanged $1 target at Citi
Citi analyst Paul Lejuez upgraded Ascena Retail to Neutral from Sell with an unchanged price target of $1.00. With the stock closing at 99c, the risk/reward is more balanced at current levels, Lejuez tells investors in a research note. He believes management will likely continue trying to monetize some of its brands following last week's announced sale of Maurice's.
KR Kroger
$24.04

-0.18 (-0.74%)

05/20/19
BERN
05/20/19
UPGRADE
BERN
Outperform
Kroger upgraded to Outperform from Market Perform at Bernstein
03/21/19
LOOP
03/21/19
NO CHANGE
Target $102
LOOP
Hold
Walmart grocery sales productivity outperforming supermarkets, says Loop Capital
Loop Capital analyst Andrew Wolf kept his Hold rating and $102 price target on Walmart (WMT), saying the company's U.S. grocery comps outperformed the supermarket chains in 2018 as it has since 2016, even though the gap has narrowed. The analyst notes that Kroger (KR) made the biggest strides last year, and that the company was also the best performer in the 2013-2015 period supermarkets last made strong market share gains. Looking ahead, Wolf says the accelerating food-price inflation anticipated by the USDA could also "bode well for continued further same-store sales acceleration for both Walmart and the grocers in 2019."
03/20/19
EVER
03/20/19
INITIATION
Target $27
EVER
In Line
Kroger initiated with an In Line at Evercore ISI
Evercore ISI analyst Michael Montani started Kroger with an In Line rating and $27 base case price target, citing his view that Kroger's efforts to build out its ecosystem are admirable, but it's too soon to expect an "Amazon-esque" flywheel to drive sustainable EBIT growth.
02/08/19
02/08/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. American Airlines (AAL) initiated with a Hold at Argus. 2. Walmart (WMT) and Sprouts Farmers Market (SFM) were initiated with a Neutral at Buckingham, while Kroger (KR) was initiated with an Underperform. 3. Wrap Technologies (WRTC) initiated with a Buy at Chardan. 4. nLight (LASR) initiated with a Hold at Craig-Hallum. 5. RA Pharmaceuticals (RARX) initiated with a Buy at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
SNAP Snap
$11.19

-0.3 (-2.61%)

04/24/19
04/24/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Buy from Hold at Edward Jones. 2. Snap (SNAP) upgraded to In Line from Underperform at Evercore ISI and to Neutral from Underweight at JPMorgan. 3. Best Buy (BBY) upgraded to Buy from Hold at Jefferies with analyst Jonathan Matuszewski saying survey and data work suggest Best Buy's greater push toward services will drive long-term value and customer wallet share. 4. Procter & Gamble (PG) upgraded to Overweight from Equal Weight at Barclays with analyst Lauren Lieberman saying the market is shrugging off Procter & Gamble's 5% organic sales growth in its fiscal Q3, with many investors thinking this is the best it can get. 5. Sonoco (SON) upgraded to Buy from Hold at Argus with analyst David Coleman saying the stock has outperformed over the past 3 months, benefiting from its "accretive acquisitions, favorable pricing, improvements in productivity, and a lower effective tax rate." This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/30/19
JMPS
04/30/19
NO CHANGE
Target $1300
JMPS
Outperform
Alphabet price target lowered to $1,300 from $1,375 at JMP Securities
JMP Securities analyst Ronald Josey said competition "may have played a role" in Alphabet's (GOOGL) worse than expected Q1 revenue given that better than expected advertising results have recently been reported by Facebook (FB), Twitter (TWTR), Snap (SNAP) and Amazon (AMZN). However, he believes the "majority of the deceleration was self-imposed," he tells investors in a post-earnings research note. Some of the company's product changes, such as changes at YouTube's recommendation engine, likely acted as a headwind, the analyst surmised. Josey sees benefits from investments in hardware and Google Cloud and thinks that multiple monetization opportunities remain for Alphabet, leading him to maintain an Outperform rating on the stock, though he lowered his price target on shares to $1,300 from $1,375.
05/13/19
RBCM
05/13/19
INITIATION
Target $28
RBCM
Sector Perform
Pinterest initiated with a Sector Perform at RBC Capital
RBC Capital analyst Mark Mahaney initiated Pinterest with a Sector Perform rating and a price target of $28. The analyst is positive on the company's "very large market opportunity" in advertising and believes that it is benefiting from "powerful" secular tailwinds, boasting a monthly active user, or MAU, count above that of Twitter (TWTR) and growing the MAUs faster than Snap (SNAP). Despite his belief than Pinterest can sustain a double-digit growth rate in MAUs and Average Revenue Per User until 2021, Mahaney sees its stock as "reasonably valued" after a 50% run-up from its IPO price.
04/24/19
JEFF
04/24/19
NO CHANGE
Target $13
JEFF
Hold
Snap shares already reflect Q1 improvements, says Jefferies
Jefferies analyst Brent Thill raised his price target for Snap to $13 from $11 but keeps a Hold rating on the shares following the company's Q1 results. Snap returned to user growth while also driving an acceleration of average revenue per user growth, Thill tells investors in a post-earnings research note. The analyst likes the trajectory of the business but believes the stock "already reflects these improvements."
NDSN Nordson
$130.42

-4.8 (-3.55%)

04/23/19
OPCO
04/23/19
NO CHANGE
Target $155
OPCO
Outperform
Nordson price target raised to $155 from $150 at Oppenheimer
Oppenheimer analyst Christopher Glynn raised his price target for Nordson to $155 from $150, while reiterating an Outperform rating on the shares. The analyst notes that the company remains focused on and confident in ability to expand deployment of core technologies to expanded vertical market applications in support of expected long-term organic growth. Glynn views the stability, as characterized by 45%-50% of sales from wear out aftermarket parts and consumables on a growing installed base, with equipment markets characterized by stable consumer nondurables and higher growth end markets.
01/08/19
OPCO
01/08/19
UPGRADE
OPCO
Outperform
Nordson upgraded to Outperform from Perform at Oppenheimer
01/08/19
OPCO
01/08/19
UPGRADE
Target $140
OPCO
Outperform
Nordson upgraded to Outperform at Oppenheimer
As previously reported, Oppenheimer analyst Christopher Glynn upgraded Nordson to Outperform from Perform, with a $140 price target. The analyst notes that the company has delivered organic growth for nine straight years through FY18, and guided FY19 for 3%-5% organic growth and 100bps-150 bps OM expansion. Organic growth was slightly negative over the prior three quarters and will certainly be so in FY1Q18 on a particularly onerous comparison, but that is all well known, he contends. While Glynn acknowledges that shares are not cheap in the current market, he expects about 110% structural free cash flow/NI long-term and 120% in FY19 on expected solid working capital execution versus historical, including some benefits from facilities consolidations at ADS.
11/29/18
DADA
11/29/18
DOWNGRADE
Target $125
DADA
Neutral
Nordson downgraded to Neutral at DA Davidson on China and trade concerns
As reported earlier, DA Davidson analyst Matt Summerville downgraded Nordson to Neutral from Buy and lowered his price target to $125 from $160 while also reducing his FY19 and FY20 EPS views by 40c to $6.20 and $6.95 respectively. The analyst believes that the current Street consensus for Nordson's Q1 and FY19 is too high because of the weaker macro environment in China - particularly in consumer electronics - as evidenced by its decline in consumer confidence since February. Summerville also points to the headwinds of trade and tariff related uncertainty as well as the adverse FX impact on the company that is expected to persist throughout FY19.
OCUL Ocular Therapeutix
$3.36

-0.1 (-2.89%)

01/04/19
PIPR
01/04/19
NO CHANGE
Target $14
PIPR
Overweight
Piper sees 'significant share appreciation' potential for Ocular Therapeutix
Ocular Therapeutix expects top-line data from OTX-TP's first Phase III glaucoma study in the first half of 2019, Piper Jaffray analyst Joseph Catanzaro tells investors in a research note. The analyst believes investors have discounted this program based on mixed Phase I/II data that utilized different formulations and study designs. However, he thinks the Phase III design gives OTX-TP the best chance at demonstrating clinical efficacy in this setting. A successful outcome will be statistically significant IOP-reductions over placebo at all time points and importantly, at least a 5 mm Hg reduction in IOP from baseline at 6 of the 9 time points, Catanzaro contends, citing his review of literature and a survey of ophthalmologists. He believes such an outcome would represent "another successful application of the hydrogel platform and drive significant share appreciation." The analyst has an Overweight rating on Ocular Therapeutix with a $14 price target.
12/04/18
HCWC
12/04/18
NO CHANGE
Target $12
HCWC
Buy
Ocular Therapeutix price target raised to $12 from $10 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Ocular Therapeutix to $12 after the FDA approved Dextenza for intracanalicular use for the treatment of ocular pain following ophthalmic surgery. The analyst believes the news should bolster confidence in the company among investors. The approval not only validates Ocular's hydrogel drug delivery platform, but endorses the incumbent management team's execution and accountability, Selvaraju tells investors in a research note. He reiterates a Buy rating on the name.
03/08/19
PIPR
03/08/19
NO CHANGE
Target $14
PIPR
Overweight
Ocular undervalued ahead of glaucoma data, says Piper Jaffray
Ahead of Dextenza's planned mid-2019 U.S. launch for post-cataract pain, Ocular Therapeutix is expected to report data from both OTX-TP and OTX-TIC in glaucoma are expected in first half of 2019, Piper Jaffray analyst Joseph Catanzaro tells investors in a research note. Now funded into 2020, Ocular shares remain undervalued for its suite of hydrogel-based products for both the front and back of the eye, Catanzaro contends. He maintains an Overweight rating on the shares with a $14 price target.
03/28/19
PIPR
03/28/19
NO CHANGE
Target $14
PIPR
Overweight
Ocular Therapeutix's Dextenza may provide substantial upside, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro kept his Overweight rating and $14 price target on Ocular Therapeutix after its R&D day highlighting the company's preparations for a mid-2019 Dextenza launch as well as the overall breadth of the hydrogel platform. The analyst believes that while Dextenza gives Ocular Therapeutix a "nice foundation", the company also has "opportunities to expand in post-ophthalmic surgery, glaucoma, dry eye, retinal disease, as well as sinusitis,osteoarthritis and post-op incisional pain." Catanzaro speculates that Ocular Therapeutix could file up to 4 Investigational New Drug submissions per year.
SWI SolarWinds
$19.16

0.04 (0.21%)

05/06/19
SBSH
05/06/19
NO CHANGE
Target $23
SBSH
Buy
SolarWinds price target raised to $23 from $20 at Citi
Citi analyst Walter Pritchard raised his price target for SolarWinds to $23 from $20 citing multiple expansion and keeps a Buy rating on the shares. The analyst continues to view SolarWinds' competitive landscape as "benign" and thinks its "high levels" of profitability are underappreciated. He keeps a Buy rating on the shares.
04/25/19
JEFF
04/25/19
NO CHANGE
Target $23
JEFF
Buy
SolarWinds price target raised to $23 from $21 at Jefferies
Jefferies analyst John DiFucci raised his price target for SolarWinds to $23 from $21 following the company's "largely in line" Q1 results. Guidance was "slightly better," excluding acquisition effects, and implies modest acceleration throughout the year, DiFucci tells investors in a research note titled "1Q19: Down the Middle." He continues to believe there is more value here than the current stock price implies and keeps a Buy rating on SolarWinds.
03/18/19
GSCO
03/18/19
DOWNGRADE
Target $20
GSCO
Neutral
SolarWinds downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Heather Bellini downgraded SolarWinds to Neutral from Buy with an unchanged price target of $20. The stock is up 36% year-to-date, and following the outperformance relative to the S&P 500 Index, there are opportunities for greater upside elsewhere in Software, Bellini tells investors in a research note. Further, the analyst's "blue sky analysis" shows that SolarWinds is most expensive on a growth-adjusted basis among the high growth software companies.
03/18/19
GSCO
03/18/19
UPGRADE
Target $94
GSCO
Buy
Okta upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Heather Bellini upgraded Okta (OKTA) to Buy from Neutral and raised her price target for the shares to $94 from $80. Okta closed Friday down 4%, or $3.67, to $79.21. The company's "strong" results since its April 2017 initial public offering continue to demonstrate the growing role that identity is playing in the wider enterprise information technology ecosystem, Bellini tells investors in a research note. She says Okta remains the leader in Identity and Access Management within the enterprise, and continues to benefit from its role as an independent, third party management platform for identity and user authentication that works across cloud environments. Her "Blue Sky scenario" has Okta beating 2020 consensus estimates by 38%. Bellini coupled the upgrade with a downgrade of SolarWinds (SWI) to Neutral from Buy.
MRCY Mercury Systems
$72.85

-0.11 (-0.15%)

01/30/19
RHCO
01/30/19
NO CHANGE
Target $63
RHCO
Buy
Mercury Systems price target raised to $63 from $58 at SunTrust
SunTrust analyst Michael Ciarmoli raised his price target on Mercury Systems to $63 and kept his Buy rating after its Q2 results, saying the company's organic revenue growth of 10.5% contributed to a top and bottom line beat. The analyst cites the company's recent design wins and strong pipeline enabling the management to raise its FY19 sales, EBITDA, and earnings outlook. Ciarmoli cautions that the company's higher R&D spending and capital expenditures may drag on its margins and free cash flows, but expects shares to trade higher given the revenue and bookings strength.
04/26/19
ADAM
04/26/19
NO CHANGE
Target $76
ADAM
Buy
Mercury Systems price target raised to $76 from $64 at Canaccord
Canaccord analyst Ken Herbert raised his price target for Mercury Systems to $76 from $64 and maintained a Buy rating ahead of the company's Q3 results on April 30. Mercury Systems has been one of the best performing A&D stocks this year, up over 50% compared to under 20% for the broader A&D small cap universe, Herbert tells investors in a research note, adding that he believes Mercury will benefit from the strong fundamentals and that recent acquisitions should help with incremental upside. Herbert likes the stock into the Q3 results, even with the recent strength, and continue to view Mercury as a core holding for small-cap exposure to the defense cycle.
02/05/19
SBSH
02/05/19
NO CHANGE
Target $68
SBSH
Buy
Citi sees path to $90 per share for Mercury Systems, ups target to $68
Citi analyst Jonathan Raviv still sees upside in shares of Mercury Systems despite the stock being up 23% year-to-date. The structural trends that support Mercury's sales growth are still intact, Raviv tells investors in a research note. Further, the company's "high degree of M&A capacity" means that it can grow above-average over time and is "therefore deserving of a premium multiple," adds the analyst. His math suggests a path to $90 per share "over time" and he upped his price target for Mercury Systems to $68 from $56. Raviv keeps a Buy rating on the name.
05/01/19
ALMG
05/01/19
UPGRADE
ALMG
Overweight
Mercury Systems upgraded to Overweight from Neutral at Alembic Global
VNE Veoneer
$18.89

0.02 (0.11%)

04/23/19
BARD
04/23/19
UPGRADE
BARD
Baird says autos attractive, upgrades Veoneer to Neutral, Visteon to Outperform
As previously reported, Baird analyst David Leiker upgraded Visteon (VC) to Outperform from Neutral and upgraded Veoneer (VNE) to Neutral from Underperform, citing his broader industry view that the recent rally in auto supplier stocks "has legs" and can be sustained into 2020 given the stabilizing end market backdrop, ongoing content growth and low valuations. While Visteon still faces "severe" near-term challenges, the company's updated backlog communication reinforces what should be the sector's fastest organic revenue growth across 2020-21, said Leiker, who raised his price target on the shares to $108 from $87. For Veoneer, he now views the risk/reward as balanced and raised his price target on those shares to $28 from $21.
04/23/19
BARD
04/23/19
UPGRADE
BARD
Neutral
Veoneer upgraded to Neutral from Underperform at Baird
05/06/19
BMOC
05/06/19
NO CHANGE
Target $30
BMOC
Outperform
Veoneer price target lowered to $30 from $38 at BMO Capital
BMO Capital analyst Richard Carlson lowered his price target on Veoneer to $30 after its Q1 earnings miss, saying the company is faced with near-term challenges in the environment of "modest decline" in the global auto building industry and higher development costs related to its "high-tech" product portfolio. Beyond the near term headwinds however, Carlson sees "significant upside" for the stock based on the multi-year increase in penetration of its Active Safety products, keeping his Outperform rating on the shares.
04/23/19
04/23/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst James Faucette citing his view that the market has "not yet fully appreciated" the impact of the company's settlement with Apple (AAPL), which he thinks not only increases earnings substantially while also expanding the freedom with which Qualcomm can pursue new opportunities. 2. Kimberly-Clark (KMB) upgraded to Buy from Hold at Argus and to Outperform from Neutral at Macquarie. 3. Sanderson Farms (SAFM) upgraded to Neutral from Sell at Goldman Sachs with analyst Adam Samuelson saying African swine fever is upending the protein markets, Samuelson tells investors in a research note. 4. Visteon (VC) upgraded to Outperform from Neutral at Baird while Veoneer (VNE) was upgraded to Neutral from Underperform. 5. Sony (SNE) upgraded to Outperform from Neutral at Macquarie. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GH Guardant Health
$78.29

2.13 (2.80%)

04/16/19
ADAM
04/16/19
INITIATION
Target $90
ADAM
Buy
Guardant Health initiated with a Buy at Canaccord
Canaccord initiated Guardant Health with a Buy and $90 price target.
04/16/19
ADAM
04/16/19
INITIATION
Target $90
ADAM
Buy
Guardant Health initiated with a Buy at Canaccord
Canaccord analyst Mark Massaro initiated Guardant Health with a Buy rating and $90 price target, saying the company is accelerating its mission to conquer cancer globally and views Guardant as the leader in liquid biopsy cancer testing. Guardant expects to submit G360 to the FDA for break-through device approval by mid-2019 and expects FDA approval by the end of 2019 or early 2020, which he thinks will reduce push back from the remaining 40% of U.S.-based oncologists who have not yet ordered.
04/10/19
BOFA
04/10/19
UPGRADE
Target $84
BOFA
Buy
Guardant Health upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Derik de Bruin upgraded Guardant Health to Buy from Neutral and raised its price target to $84 from $81 citing growth potential despite the recent run in shares. de Bruin aid Guardant Health is a leader in liquid biopsy-based cancer testing and said expectations remain reasonable following the lock-up expiration, LUNAR-1 data release, G360 expanded coverage, and a review of the liquid-biopsy testing market.
05/10/19
JPMS
05/10/19
NO CHANGE
Target $90
JPMS
Overweight
Guardant Health price target raised to $90 from $85 at JPMorgan
JPMorgan analyst Tycho Peterson raised his price target for Guardant Health to $90 from $85 saying the company last night reported "strong" Q1 results. Th analyst continues to view Guardant as a "best-in-class asset in the attractive liquid biopsy space." He sees upside from current share levels and keeps an Overweight rating on the name.
CVNA Carvana
$67.17

-0.935 (-1.37%)

05/20/19
COWN
05/20/19
INITIATION
Target $81
COWN
Outperform
Carvana initiated with an Outperform at Cowen
Cowen analyst Thomas Champion initiated Carvana with an Outperform rating and $81 price target, telling investors that his recent auto-buyer survey points towards the company gaining share in the online used car retail market. He notes that the company has high customer satisfaction and repeat purchase intent while also highlighting Carvana's improving unit economics.
05/09/19
BARD
05/09/19
NO CHANGE
Target $85
BARD
Outperform
Carvana price target raised to $85 from $65 at Baird
Baird analyst Colin Sebastian raised his price target on Carvana shares to $85 from $65 to reflect his increased estimates and what he views as the company's "impressive execution" and "massive growth opportunity." The company's unit sales outperformance in Q1 while sequentially narrowing its operating losses is a positive sign on the long-term scalability of its model, contends Sebastian, who keeps an Outperform rating on Carvana.
05/09/19
WELS
05/09/19
NO CHANGE
Target $85
WELS
Outperform
Carvana price target raised to $85 from $80 at Wells Fargo
Wells Fargo analyst Zachary Fadem raised his price target for Carvana to $85 from $80 after the company delivered another quarter of "robust" top line results, and an uptick in the 2019 outlook. The analyst reiterates an Outperform rating on the shares.
05/13/19
BMOC
05/13/19
NO CHANGE
Target $65
BMOC
Market Perform
Carvana price target raised to $65 from $55 at BMO Capital
BMO Capital analyst Daniel Salmon raised his price target on Carvana to $65 after its 21st consecutive quarter of triple-digit revenue growth, saying the company's execution remains "strong" and the consumer demand for its offerings still "robust." Despite the 490bps EBITDA margin improvement in Carvana's Q1 results however, the analyst remains concerned about the company's near-term path to profitability and free-cash-flow generation capacity, keeping his Market Perform rating on the stock.
INSM Insmed
$28.08

-1.08 (-3.70%)

03/08/19
ADAM
03/08/19
NO CHANGE
Target $44
ADAM
Buy
Insmed price target raised to $44 from $32 at Canaccord
Canaccord analyst Dewey Steadman raised his price target on Insmed to $44 from $32 following Q4 results. The analyst was impressed with the Arikayce uptake to-date and he thinks its initial guidance leaves room for a beat once Medicare dynamics are fully understood. He also sees continued growth in the Arikayce franchise and its pulmonary pipeline provides additional upside optionality. Steadman reiterated his Buy rating on Insmed shares.
04/09/19
HCWC
04/09/19
NO CHANGE
Target $52
HCWC
Buy
Insmed price target raised to $52 from $43 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised his price target for Insmed to $52 from $43 saying the company yesterday announced a positive update on the U.S. launch of Arikayce. The broadening of the prescriber base "is not short lived and can continue, as well as possibly be supplemented by label expansion into first line patients," Fein tells investors in a research note. He keeps a Buy rating on the shares.
02/15/19
JMPS
02/15/19
UPGRADE
Target $40
JMPS
Outperform
Insmed upgraded to Outperform following Arikayce survey at JMP Securities
As previously reported, JMP Securities analyst Liisa Bayko upgraded Insmed to Outperform from Market Perform, stating that her survey of "early adopters" of Arikayce shows a high rate of utilization with a favorable early experience that is encouraging more usage. This suggests Arikayce will beat 2019 consensus, contends Bayko, who raised her 2019 Arikayce revenue estimates. She set a $40 price target on Insmed shares.
03/26/19
STFL
03/26/19
NO CHANGE
Target $43
STFL
Buy
Pulmonologist call reinforces Stifel view of upside for Insmed
After hosting a conference call with two key opinion leader pulmonologists to discuss the rollout of Arikayce, Stifel analyst Adam Walsh said their feedback suggested the strong start for the drug was not the result of a "bolus" of patients awaiting approval and noted that both doctors said their new-patient starts remain steady. While it "remains early days in the launch," the call with the doctors reinforced his belief that Insmed's Arikayce guidance is likely conservative, Walsh tells investors. He keeps a Buy rating and $43 price target on Insmed shares.
VAR Varian Medical
$130.48

-0.26 (-0.20%)

04/04/19
BRRR
04/04/19
NO CHANGE
Target $150
BRRR
Outperform
Varian Medical price target raised to $150 from $135 at Barrington
Barrington analyst Michael Petusky raised his price target for Varian Medical Systems to $150 from $135 after the company disclosed the initial preclinical results of its research on ultra-high dose cancer treatment utilizing protons at the American Association for Cancer Research meeting. The analyst views the early results as "encouraging" and adds that order momentum at Varian over the past several months "has been extremely strong." He keeps an Outperform rating on the shares.
03/22/19
BARD
03/22/19
UPGRADE
BARD
Outperform
Varian Medical upgraded to Outperform from Neutral at Baird
03/22/19
BARD
03/22/19
UPGRADE
Target $162
BARD
Outperform
Varian Medical upgraded to Outperform from Neutral at Baird
Baird analyst Jason Bednar upgraded Varian Medical to Outperform from Neutral and raised his price target to $162 from $127. In a research note to investors, Bednar says that with near-term trends sounding healthy, multiple paths are emerging for Varian to sustain upper-single digit plus oncology order growth, and low- to mid-teens EPS growth looking increasingly likely and sustainable into fiscal 2020 and beyond, he believes Varian is quickly becoming a premium medech grower and a stock that investors can consider a core medtech holding.
03/22/19
03/22/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pearson (PSO) upgraded to Overweight from Neutral at JPMorgan with analyst Daniel Kerven saying the company's business model is improving as its moves from print to digital. 2. Lumentum (LITE) upgraded to Overweight from Neutral at JPMorgan with analyst Samik Chatterjee seeing a "solid" outlook for the company's telecom business amid "strong" growth led by 5G investments and upside to synergy targets relative to recent acquisition of Oclaro. 3. Best Buy (BBY) upgraded to Outperform from Perform at Oppenheimer with analyst Brian Nagel stating the company has undergone a significant transformation under the direction of new senior leadership to one of retail's preeminent omnichannel operators. 4. Varian Medical (VAR) upgraded to Outperform from Neutral at Baird with analyst Jason Bednar saying that with near-term trends sounding healthy, multiple paths are emerging for Varian to sustain upper-single digit plus oncology order growth, and low- to mid-teens EPS growth. 5. Chipotle (CMG) upgraded to Neutral from Underperform at Wedbush with analyst Nick Setyan noting he no longer sees risk to near- and medium-term same-store sales growth and unit-level margin expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

BX

Blackstone

$44.39

-0.66 (-1.47%)

14:05
06/24/19
06/24
14:05
06/24/19
14:05
Periodicals
Blackstone to sell Landmark Financial for roughly $600M, Reuters says »

Blackstone has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCCY

1st Constitution Bancorp

$18.00

-0.695 (-3.72%)

, SHRC

Shore Community Bank

$0.00

(0.00%)

14:05
06/24/19
06/24
14:05
06/24/19
14:05
Upgrade
1st Constitution Bancorp, Shore Community Bank rating change  »

1st Constitution Bancorp…

FCCY

1st Constitution Bancorp

$18.00

-0.695 (-3.72%)

SHRC

Shore Community Bank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATHX

Athersys

$1.77

0.03 (1.72%)

14:04
06/24/19
06/24
14:04
06/24/19
14:04
Conference/Events
Athersys management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

VZ

Verizon

$58.25

0.46 (0.80%)

, FDX

FedEx

$161.57

-3.74 (-2.26%)

14:04
06/24/19
06/24
14:04
06/24/19
14:04
Periodicals
Huawei's Futurewei separates operations from corporate parent, Reuters says »

The U.S.-based research…

VZ

Verizon

$58.25

0.46 (0.80%)

FDX

FedEx

$161.57

-3.74 (-2.26%)

MSFT

Microsoft

$137.85

0.91 (0.66%)

LITE

Lumentum

$50.39

1.02 (2.07%)

FN

Fabrinet

$49.13

-0.54 (-1.09%)

CIEN

Ciena

$42.87

-0.64 (-1.47%)

NPTN

NeoPhotonics

$4.06

-0.02 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 26

    Jun

  • 27

    Jun

  • 09

    Jul

  • 10

    Jul

  • 30

    Jul

  • 31

    Jul

  • 01

    Aug

  • 06

    Aug

  • 13

    Nov

RAMP

LiveRamp

$49.64

-1.485 (-2.90%)

, NLSN

Nielsen

$22.57

-0.85 (-3.63%)

14:01
06/24/19
06/24
14:01
06/24/19
14:01
Recommendations
LiveRamp, Nielsen, comScore analyst commentary  »

LiveRamp acquisition of…

RAMP

LiveRamp

$49.64

-1.485 (-2.90%)

NLSN

Nielsen

$22.57

-0.85 (-3.63%)

SCOR

comScore

$7.40

-0.37 (-4.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

LAUR

Laureate Education

$15.20

-0.17 (-1.11%)

14:00
06/24/19
06/24
14:00
06/24/19
14:00
Options
Odd bullish block in Laureate Education on CBOE »

Odd bullish block in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCCY

1st Constitution Bancorp

$18.00

-0.695 (-3.72%)

13:59
06/24/19
06/24
13:59
06/24/19
13:59
Upgrade
1st Constitution Bancorp rating change  »

1st Constitution Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BYND

Beyond Meat

$143.15

-10.925 (-7.09%)

13:58
06/24/19
06/24
13:58
06/24/19
13:58
Hot Stocks
PizzaRev announces partnership to offer Beyond Meat sausage topping »

PizzaRev announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:55
06/24/19
06/24
13:55
06/24/19
13:55
General news
Fed funds futures are firmer with Treasuries »

Fed funds futures are…

KPTI

Karyopharm

$6.30

-0.13 (-2.02%)

13:50
06/24/19
06/24
13:50
06/24/19
13:50
Options
Bullish call spread opened in Karyopharm Therapeutics »

Bullish call spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jul

FDS

FactSet

$293.78

-4.31 (-1.45%)

, LEN

Lennar

$51.67

0.35 (0.68%)

13:46
06/24/19
06/24
13:46
06/24/19
13:46
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

FDS

FactSet

$293.78

-4.31 (-1.45%)

LEN

Lennar

$51.67

0.35 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 25

    Jun

  • 27

    Jun

  • 28

    Jun

SPOT

Spotify

$149.91

1.74 (1.17%)

, AAPL

Apple

$199.07

0.3 (0.15%)

13:46
06/24/19
06/24
13:46
06/24/19
13:46
On The Fly
Analyst says sell Spotify on publisher rates risk, competition »

Evercore ISI analyst…

SPOT

Spotify

$149.91

1.74 (1.17%)

AAPL

Apple

$199.07

0.3 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

STNG

Scorpio Tankers

$26.23

0.18 (0.69%)

13:45
06/24/19
06/24
13:45
06/24/19
13:45
Conference/Events
Scorpio Tankers management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

AG

First Majestic

$7.77

0.31 (4.16%)

13:45
06/24/19
06/24
13:45
06/24/19
13:45
Options
First Majestic call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHRS

Coherus Biosciences

$21.23

-0.51 (-2.35%)

13:43
06/24/19
06/24
13:43
06/24/19
13:43
Conference/Events
Coherus Biosciences management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

MDEVF

Melco International

$0.00

(0.00%)

, MLCO

Melco Resorts & Entertainment

$21.41

-0.21 (-0.97%)

13:40
06/24/19
06/24
13:40
06/24/19
13:40
Recommendations
Melco International, Melco Resorts & Entertainment analyst commentary  »

Melco International could…

MDEVF

Melco International

$0.00

(0.00%)

MLCO

Melco Resorts & Entertainment

$21.41

-0.21 (-0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMB

Williams

$27.24

-0.45 (-1.63%)

13:35
06/24/19
06/24
13:35
06/24/19
13:35
Options
Williams put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLSA

Tiziana Therapeutics

$8.50

(0.00%)

13:32
06/24/19
06/24
13:32
06/24/19
13:32
Hot Stocks
Tiziana says newly published article supports oral monoclonal antibody platform »

Tiziana Life Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTES

NetEase

$262.82

0.42 (0.16%)

13:25
06/24/19
06/24
13:25
06/24/19
13:25
Options
NetEase call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$199.18

0.41 (0.21%)

13:21
06/24/19
06/24
13:21
06/24/19
13:21
Periodicals
Apple rolls out fifth iOS 12.4 beta ahead of Apple Card launch, 9to5Mac says »

Apple is rolling out the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
06/24/19
06/24
13:17
06/24/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFMD

Affimed N.V.

$2.97

-0.45 (-13.16%)

13:16
06/24/19
06/24
13:16
06/24/19
13:16
Hot Stocks
Affimed falls 13% after announcing clinical update on AFM13 in CD30 lymphomas »

Earlier today, Affimed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
06/24/19
06/24
13:16
06/24/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSIT

Insight Enterprises

$56.89

0.7 (1.25%)

, PCMI

PCM, Inc.

$34.67

10.315 (42.36%)

13:13
06/24/19
06/24
13:13
06/24/19
13:13
Recommendations
Insight Enterprises, PCM, Inc. analyst commentary at Stifel »

Insight Enterprises price…

NSIT

Insight Enterprises

$56.89

0.7 (1.25%)

PCMI

PCM, Inc.

$34.67

10.315 (42.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

NBL

Noble Energy

$21.32

-0.24 (-1.11%)

, OXY

Occidental Petroleum

$50.09

-0.53 (-1.05%)

13:07
06/24/19
06/24
13:07
06/24/19
13:07
Periodicals
U.S. natural gas prices plummet in June, Forbes says »

According to Jude…

NBL

Noble Energy

$21.32

-0.24 (-1.11%)

OXY

Occidental Petroleum

$50.09

-0.53 (-1.05%)

EOG

EOG Resources

$90.84

-1.57 (-1.70%)

DVN

Devon Energy

$27.93

-0.31 (-1.10%)

APA

Apache

$29.14

-0.52 (-1.75%)

CHK

Chesapeake

$1.89

-0.055 (-2.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 02

    Aug

  • 27

    Aug

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.